Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 9c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.05 +1.41%
Revenue Growth %: +24.1%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
OCCI, IPX, ALZN, More
Revenue Growth %: +24.1%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of ($0.08), $0.09 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $53.2 million versus the consensus estimate of $51.23 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2025 revenue of $210-250 million, versus the consensus of $284.9 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
- HeartSciences (HSCS) files $200M mixed shelf
- NeuroSense posts narrower H1 loss, targets Canada drug filing by December
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
